Gonal-f Rff is a drug owned by Emd Serono Inc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 16, 2015. Details of Gonal-f Rff's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5767067 | Follicle stimulating hormone and pharmaceutical compositions containing same |
Jun, 2015
(9 years ago) |
Expired
|
| US5767251 | Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof |
Jun, 2015
(9 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Gonal-f Rff is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Gonal-f Rff's family patents as well as insights into ongoing legal events on those patents.
Gonal-f Rff's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Gonal-f Rff's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 16, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Gonal-f Rff Generics:
There are no approved generic versions for Gonal-f Rff as of now.
Alternative Brands for Gonal-f Rff
There are several other brand drugs using the same active ingredient (Follitropin Alfa/beta) as Gonal-f Rff. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Emd Serono |
| ||
| Organon Usa Inc |
|
About Gonal-f Rff
Gonal-F Rff is a drug owned by Emd Serono Inc. Gonal-F Rff uses Follitropin Alfa/Beta as an active ingredient. Gonal-F Rff was launched by Emd Serono in 2004.
Approval Date:
Gonal-f Rff was approved by FDA for market use on 25 March, 2004.
Active Ingredient:
Gonal-f Rff uses Follitropin Alfa/beta as the active ingredient. Check out other Drugs and Companies using Follitropin Alfa/beta ingredient
Dosage:
Gonal-f Rff is available in injectable form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 75 IU/VIAL | INJECTABLE | Prescription | SUBCUTANEOUS |